Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.

Abstract: A stable liquid pharmaceutical preparation of an anti-influenza virus antibody and, more specifically, a stable liquid pharmaceutical preparation that comprises: (A) an anti-influenza virus antibody or a mixture of two or more different types of anti-influenza virus antibodies; (B) a surfactant; (C) a sugar or a sugar derivative; and (D) an amino acid. The stable liquid pharmaceutical preparation for an anti-influenza virus antibody disclosed herein has excellent storage stability at low temperature (5° C.), room temperature (25° C.), and high temperature (40° C.) and excellent long-term (12 months) storage stability, and may be administered intravenously, intramuscularly, transdermally, subcutaneously, intraperitoneally, topically, or in combinations thereof.

Abstract: A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: An apparatus for constructing a library for deriving a material composition using empirical result, which enables acceleration of research on the material-properties relationship. By applying the empirical results of the material composition, missing data of the material compositions can be statistically calculated by using supervised non-linear imputation techniques. The completed composition information of the materials is passed as an input of machine learning material-properties relationship prediction.

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.

Abstract: Disclosed is a magnetic field shielding unit for wireless power transmission. The magnetic field shielding unit for wireless power transmission includes a magnetic shielding layer formed of ferrite fragments containing magnesium oxide (MgO) shredded to improve flexibility of the magnetic field shielding unit. The ferrite containing magnesium oxide has a real part (??) of the complex permeability of 650 or more at a frequency of 100 kHz. Accordingly, it is possible to prevent influence of a magnetic field on components of a mobile terminal device or a body of a user who uses the same, and to further increase the characteristics of the combined antennas even if the magnetic field shielding unit is combined with various kinds and purposes of antennas having various structures, shapes, sizes and intrinsic characteristics (inductance, resistivity, etc.).

Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.

Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.

Abstract: This invention relates to a cosmetic composition, which controls sebum secretion of the scalp to thus create an optimal environment for hair growth and activates growth factors for promoting hair strengthening and growth, thereby improving the health of the scalp. A method of preparing the same is also provided. In the cosmetic composition, an oligopeptide functions to create an environment suitable for hair growth by controlling the sebum secretion of the scalp, and also to activate growth factors that are effective at preventing hair loss by promoting hair growth through improvement of blood circulation in the scalp and by strengthening hair through hair follicle activity, thereby improving the health of the scalp and preventing hair loss. The oligopeptide of the invention can exhibit high safety and stability of use and high absorbability into the skin and is thus excellent in improving the health of the scalp, compared to the use of existing peptide compositions.

Abstract: An electronic component and a board having the same are provided. The electronic component according to an exemplary embodiment in the present disclosure may include a body having upper and lower surfaces, first and second side surfaces, and third and fourth side surfaces; external electrodes disposed on at least one of the upper and lower surfaces and the third and fourth side surfaces of the body; and connection terminals disposed on the external electrodes, wherein the connection terminals are disposed inwardly to be spaced apart from an edge of a surface of the body on which the connection terminals are disposed.

Abstract: An electronic component and a board having the same are provided. The electronic component according to an exemplary embodiment in the present disclosure may include a body having upper and lower surfaces, first and second side surfaces, and third and fourth side surfaces; external electrodes disposed on at least one of the upper and lower surfaces and the third and fourth side surfaces of the body; and connection terminals disposed on the external electrodes, wherein the connection terminals are disposed inwardly to be spaced apart from an edge of a surface of the body on which the connection terminals are disposed.

Abstract: Provided herein is a device for discharging ink using electrostatic force, the device including a nozzle portion for discharging ink through an electric field to a substrate; an electrode portion for creating an electric field between the nozzle and the substrate; and a gas discharge portion for discharging guide gas from outside of the nozzle portion to control a cross-section area of ink being discharged from the nozzle portion.

Abstract: Provided herein a device for discharging ink, the device comprising: a nozzle body comprising a chamber for accommodating ink, and a nozzle for discharging the ink to one surface of a target object; an electrode portion attached to or distanced from the nozzle body; a signal generator for applying a voltage to the electrode portion so that electrons may be induced to a liquid surface of the ink and an electrostatic force may be formed, the voltage being lower than a predetermined discharge critical voltage; a nozzle body driver for moving the nozzle body; and a controller for controlling the nozzle body driver to adjust a distance between the nozzle and the one surface of the target object so that an electrostatic force corresponding to the voltage higher than the discharge critical voltage may be formed and thus the ink may be discharged.

Abstract: Disclosed are peptide derivatives, wherein glutathione-like peptides are connected to benzoic acid derivatives, and a cosmetic composition comprising the same. The peptide derivatives have excellent tyrosinase inhibition and anti-oxidative activities to show excellent skin whitening effect, biocompatibility without skin stimulation, and stability during long-term storage. Therefore, they can be effectively used for a cosmetic composition for skin whitening.

Abstract: Provided is a caffeoylalphaneoendrophin peptide derivative, and use thereof, as an anti-itching agent and an anti-atopic agent. More specifically, provided is a caffeoyl endorphin peptide derivative, which is applicable in a cosmetic material for anti-inflammatory use, such as for an atopic dermatitis treatment, and the like. The caffeoyl endorphin peptide derivative is safe for skin, has resistance to degradation by peptidases, and the like, and also has an excellent stability with respect to temperature change, and the like.

Abstract: Disclosed herein is an apparatus and method for balancing the color of a flashed image using depth estimation. The apparatus includes a depth value measurement unit, a region identification unit, a color impression estimation unit, and a color balancing unit. The depth value measurement unit measures the depth values of the respective regions of an image to be captured using a camera preview image. The region identification unit identifies the regions of the preview image as a region influenced by camera flash or a region not influenced by camera flash using the depth values measured by the depth value measurement unit. The color impression estimation unit estimates the color impression of actual illumination in the region not influenced by camera flash. The color balancing unit corrects the color of the region influenced by camera flash.

Abstract: Disclosed herein is an apparatus for enhancing images in consideration of region characteristics. An inverse gamma correction unit releases gamma correction and linearizes each of Red (R), Green (G), and Blue (B) colors. A threshold calculation unit calculates m-1 thresholds in order to divide the brightness of pixels into m regions, and labels each of the pixels as one of the m brightness regions. A block segmentation unit divides an input image into M×N blocks. A block statistics calculation unit determines one of the m brightness regions to which each of the blocks pertains, and labels the block as the corresponding brightness region. A block-based Look-Up Table (LUT) generation unit generates enhancement LUTs for the respective blocks. An image enhancement unit corrects the image using the LUTs for the respective blocks. A gamma correction unit performs gamma correction.

Abstract: The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-?-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component.